Physician profile
Monica E Doerr
NPI 1952337271
$11,260.77
in general payments reported to CMS, 2019-2025
41 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $1,160 · 2021: $3,149 · 2022: $1,881 · 2023: $1,315 · 2024: $1,325 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,114 · Education: $49.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,113.90 |
| Education | $49.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,934.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,716.33 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Bayer Healthcare Pharmaceuticals INC. | $794.52 | 2021-2025 | |
| Abbott Laboratories | $600.79 | 2020-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $573.40 | 2020-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $565.70 | 2020-2025 | Jardiance, Synjardy |
| Amgen INC. | $469.91 | 2019-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $316.74 | 2019-2025 | Synthroid |
| Sanofi-Aventis U.S. LLC | $315.34 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $307.66 | 2019-2024 | Farxiga |
| Cequr Corporation | $304.85 | 2022-2025 | Cequr Simplicity |
| Medtronic Minimed, INC. | $276.50 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $198.67 | 2021-2025 | Keveyis, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $191.51 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $189.97 | 2021-2025 | Dexcom G6 Transmitter |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Doerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.